BCAX
Bicara Therapeutics

76
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald Analysts Lower Earnings Estimates for BCAX
Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Bicara Therapeutics in a research note issued on...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Equities Analysts Issue Forecasts for BCAX FY2025 Earnings
Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Bicara Therapeutics in a research report issued...
MarketBeat·2d ago
News Placeholder
Nan Fung Trinity HK Ltd. Takes Position in Bicara Therapeutics Inc. $BCAX
Nan Fung Trinity HK Ltd. purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the second quarter, according to its most recent filing with the Securities and...
MarketBeat·3d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Tuesday...
MarketBeat·4d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) issued its earnings results on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of...
MarketBeat·5d ago
News Placeholder
Bicara Therapeutics' (BCAX) "Outperform" Rating Reaffirmed at Wedbush
Wedbush reaffirmed an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Monday...
MarketBeat·5d ago
News Placeholder
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology PR Newswire NEW...
PR Newswire·20d ago
News Placeholder
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?
The consensus price target hints at an 187.7% upside potential for Bicara Therapeutics Inc. (BCAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·3mo ago

Latest BCAX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.